右美托咪定在需要无创通气的急重症成人中的安全性与疗效:随机试验的系统评价与Meta分析
该系统评价与Meta分析纳入12项随机对照试验共738例在ICU因急性呼吸衰竭启动无创通气的成人患者,比较右美托咪定与其他镇静策略或安慰剂。结果显示右美托咪定降低插管风险(RR 0.54,95%CI 0.41-0.71,中等确定性)、谵妄风险(RR 0.34,95%CI 0.22-0.54,中等确定性)和ICU住院时间(平均差-2.40天,95%CI -3.51至-1.29天,低确定性),但增加心动过缓(RR 2.80,95%CI 1.92-4.07,中等确定性)和低血压(RR 1.98,95%CI 1.32-2.98,中等确定性)风险。作者认为结果受不精确性限制,需要进一步大型随机对照试验。
要点
- 在ICU因急性呼吸衰竭启动无创通气的成人中,右美托咪定较其他镇静策略或安慰剂降低插管风险(RR 0.54,95%CI 0.41-0.71,中等确定性)。
- 右美托咪定降低谵妄风险(RR 0.34,95%CI 0.22-0.54,中等确定性)并缩短ICU住院时间(平均差-2.40天,95%CI -3.51至-1.29天,低确定性)。
- 右美托咪定增加心动过缓风险(RR 2.80,95%CI 1.92-4.07,中等确定性)和低血压风险(RR 1.98,95%CI 1.32-2.98,中等确定性)。
- 作者认为结果受不精确性限制,需要进一步大型随机对照试验。
适用人群与场景
- 在ICU因急性呼吸衰竭启动无创通气的成人患者。
研究设计与关键结果
- 系统评价与Meta分析纳入12项随机对照试验共738例患者,比较右美托咪定与其他镇静策略或安慰剂。
- 右美托咪定较其他镇静策略或安慰剂降低插管风险(RR 0.54,95%CI 0.41-0.71,中等确定性)。
- 右美托咪定降低谵妄风险(RR 0.34,95%CI 0.22-0.54,中等确定性)。
- 右美托咪定缩短ICU住院时间(平均差-2.40天,95%CI -3.51至-1.29天,低确定性)。
- 右美托咪定增加心动过缓风险(RR 2.80,95%CI 1.92-4.07,中等确定性)。
- 右美托咪定增加低血压风险(RR 1.98,95%CI 1.32-2.98,中等确定性)。
证据类型、等级与局限
- 证据类型:随机对照试验的系统评价与Meta分析。
- 插管、谵妄、心动过缓、低血压结局的证据确定性为中等,ICU住院时间结局的证据确定性为低。
- 局限:作者指出结果受不精确性限制,需要进一步大型随机对照试验。
对床旁实践的改变
- 在ICU因急性呼吸衰竭启动无创通气的成人中,右美托咪定较其他镇静策略或安慰剂降低插管、谵妄风险和ICU住院时间,但增加心动过缓与低血压风险。
- 作者认为结果受不精确性限制,需要进一步大型随机对照试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Although clinical studies have evaluated dexmedetomidine as a strategy to improve noninvasive ventilation (NIV) comfort and tolerance in patients with acute respiratory failure (ARF), their results have not been summarized.
RESEARCH QUESTION: Does dexmedetomidine, when compared with another sedative or placebo, reduce the risk of delirium, mortality, need for intubation and mechanical ventilation, or ICU length of stay (LOS) in adults with ARF initiated on NIV in the ICU?
STUDY DESIGN AND METHODS: We electronically searched MEDLINE, EMBASE, and the Cochrane Library from inception through July 31, 2020, for randomized clinical trials (RCTs). We calculated pooled relative risks (RRs) for dichotomous outcomes and mean differences (MDs) for continuous outcomes with the corresponding 95% CIs using a random-effect model.
RESULTS: Twelve RCTs were included in our final analysis (n = 738 patients). The use of dexmedetomidine, compared with other sedation strategies or placebo, reduced the risk of intubation (RR, 0.54; 95% CI, 0.41-0.71; moderate certainty), delirium (RR, 0.34; 95% CI, 0.22-0.54; moderate certainty), and ICU LOS (MD, -2.40 days; 95% CI, -3.51 to -1.29 days; low certainty). Use of dexmedetomidine was associated with an increased risk of bradycardia (RR, 2.80; 95% CI, 1.92-4.07; moderate certainty) and hypotension (RR, 1.98; 95% CI, 1.32-2.98; moderate certainty).
INTERPRETATION: Compared with any sedation strategy or placebo, dexmedetomidine reduced the risk of delirium and the need for mechanical ventilation while increasing the risk of bradycardia and hypotension. The results are limited by imprecision, and further large RCTs are needed.
TRIAL REGISTRY: PROSPERO; No.: 175086; URL: www.crd.york.ac.uk/prospero/.
参考来源
- Lewis K, Piticaru J, Chaudhuri D, et al. Safety and Efficacy of Dexmedetomidine in Acutely Ill Adults Requiring Noninvasive Ventilation: A Systematic Review and Meta-analysis of Randomized Trials. Chest. 2021. PMID: 33434496. doi:10.1016/j.chest.2020.12.052
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。